Tag - pharmaceutical stocks

Sheaff Brock Investment Advisors - post-election investment strategies

In the Wake of the Election, Looking to the Long Term

“Myths abound, but when it comes to your portfolio, it doesn’t matter much which party winds up in the White House,” at least according to Anne Kates Smith, senior editor of the Kiplinger Report. Conventional wisdom might suggest that Republicans are more “business-friendly” than Democrats, yet when we look back to 1900, it appears Democrats have actually been slightly better for stocks. Dave Gilreath, Sheaff Brock’s Chief Investment Officer, isn’t getting rattled by the post-election turmoil, either. Gilreath’s outlook on [...]

pharmaceutical manufacturing and investments | sheaff brock investment advisors

After the Recent Election, There’s New Reason to Love the Unloved

In certain oversold industries, it’s been a long, long stretch with stocks deprived of investors’ love and appreciation, observes Sheaff Brock Chief Investment Officer Dave Gilreath. Over-regulation and disfavor have swung the “affection pendulum” away from certain basic areas of our economy, Gilreath points out, including: pharmaceuticals industrials “traditional” energy (coal, natural gas, oil) After all, Gilreath reasons, with an aging population, the importance of pharmaceuticals and medical devices isn’t going away. Similarly, as the Energy Xchange emphasizes, “renewables have [...]